Biotech in Cannabis-cloning signs partnership for US market access
VANCOUVER, BC and REHOVOT, ISRAEL – BioHarvest Sciences , a leading biotech company focused on plant bio-cells growth for the nutraceutical and the medicinal cannabis markets, today announced a partnership with Royal Emerald Pharmaceuticals (REP), one of only seven Drug Enforcement Administration (DEA) bulk manufacturing registration holders to grow marijuana in the United States. This follows BioHarvest’s October 25th announcement that it could produce unique compositions based on a CBD hemp plant that dramatically increase cannabinoid concentrations (by weight) versus the original plant. The partnership enables BioHarvest to sell its cannabis products to research institutions and other DEA-registered entities in the United States federally, and opens the door to advance cannabis research initiatives through cannabinoid compositions not found in nature. Under the multi-year deal, BioHarvest will be REP’s exclusive provider of cannabis that is produced from non-traditional cultivatio...